DMSO is used as a cryoprotectant for long-term storage of auto-PBSCs. It is considered to be relatively safe, although several side effects have been associated with its infusion, including nausea, vomiting, chills, rigors, flushing, fever, dyspnea, anaphylaxis and cardiovascular events, such as bradyarrhythmia or hypotension. Central nervous systemrelated complications after DMSO administration during auto-PBSC transplantation are rare, headache being the most common. We would like to report one case of ischemic stroke during the administration of DMSOcryopreserved auto-PBSC.
A 57-year-old male was admitted to our institution for undergoing auto-SCT. He had neither hypertension nor diabetes, although mild hypertriglyceridemia had been detected in a routine test, which was controlled with diet and regular physical exercise. Conditioning regimen consisted of melphalan 200 mg/m 2 total dose (100 mg/m 2 on days À2 and À1). PBSC were infused on day 0 through a central catheter after 50 mg hydrocortisone and 10 mg of dexchlorpheniramine maleate. Stem cell bags were thawed at 37 1C in a water bath and infused at a rate of 10 mL/min. Before the infusion, patient's blood pressure was 145/90 mm Hg. Close to the end of the infusion the patient vomited and started with dyspnea, low oxygen saturation (83%) that improved with oxygen therapy at 4 L/min. At the end of the infusion, the patient experienced dizziness, became unresponsive to noxious stimuli and finally, lost consciousness and showed conjugated deviation of his eyes to the right. Pulse rate was 110 per minute and blood pressure was 90/60. Around 5 min later he developed a tonic seizure. A vol of 8 mg of i.v. diazepam and 1 g of levetiracetam were administered with improvement. Blood counts, electrolytes, liver function tests, glucose levels and cardiac enzymes remained within normal limits. An electrocardiogram was normal. He maintained stable vital signs and was in post-critical status for 1 h. Progressively the patient regained consciousness. Around 2 h after the episode he was alert with intact attention and obeying orders but he had dysarthria and right hemiparesis. A cranial computerized tomography performed at that time was normal, and the presence of stenosis of the cerebral arteries was excluded. This was also ruled out in the supra-aortic arteries, assessed by Dopplerultrasonography. An echocardiography was also normal. 72 h after the episode neurological examination showed right cheiro-oral hypoesthesia without motor impairment. Brain MRI revealed bilateral established ischemic lesions in grey and white matter and lesions in the left thalamus. At the re-evaluation of day þ 100 the patient mobilized the four limbs with mild loss of sensitivity of right hand as the single residual neurological impairment.
Neurological complications following stem cell infusion of DMSO cryopreserved cells are rare. In February 2009 Marcacci et al.,
1 summarized all the reported cases of neurological adverse events related to the infusion of DMSO-cryopreserved autologous stem cell products and suggested a predisposing role of preconditioning exposure to central nervous system-penetrating agents that may have facilitated the neurotoxic action of DMSO.
Hoyt et al. 2 were the first to suggest an enhanced risk of cerebral ischemia related to DMSO infusion. In addition, it has been reported that among the areas specially vulnerable to chemotherapy-induced neural cell damage are the brain stem, the hippocampus and the thalamus, 3-5 as we have found in our patient. Nevertheless, as the episode described in our patient started with dizziness and loss of consciousness, the event probably involved initially the whole brain, maybe in the context of hypoperfusion due to prolonged hypotension of diffuse vasospasm, which finally led to the infarction of the thalamus, that is, as it has just been mentioned, among the most vulnerable areas.
Some groups have linked neural toxicity to the amount of DMSO infused (maximal recommended dose is 1000 mg/kg) and/or to infusion rate. 6 These rates were not achieved in our patient, as the total dose administered was 560 mg/kg. Nevertheless, Junior et al. 7 and Abdelfeki et al. 8 suggested that DMSO toxicity could also be idiosyncratic.
This case illustrates the potential central nervous system toxicity after PBSC transplantation. Further studies are needed to assess the physiopathology of central nervous system ischemic complications after the administration of DMSO-cryopreserved APSC. These, although rare, may occur during the infusion. In this patient the close temporal relation between the DMSO administration and the neurological episode seems clear, although the event could also have been unrelated to DMSO. The suggestion 9 that a lower proportion of DMSO may be safer and less toxic to the hematopoietic progenitors should be also tested.
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